Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

Prevalence of neutralising antibodies to interferon-beta and clinical response in Chinese patients with relapsing multiple sclerosis.

Lau AY, Ip WK, Au C, Lau KK, Wong W, Yip KK, Yeung J, Li SH, Li P, Lee R, Siu D, Abrigo J, Wong A, Mok V, Chan E.

Mult Scler J Exp Transl Clin. 2017 Oct 9;3(4):2055217317733485. doi: 10.1177/2055217317733485. eCollection 2017 Oct-Dec.

2.

Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases.

Dreesen E, Bossuyt P, Mulleman D, Gils A, Pascual-Salcedo D.

Clin Pharmacol. 2017 Oct 3;9:101-111. doi: 10.2147/CPAA.S138414. eCollection 2017. Review.

3.

Development and Validation of an Enzyme-Linked Immunosorbent Assay for the Detection of Binding Anti-Drug Antibodies against Interferon Beta.

Ingenhoven K, Kramer D, Jensen PE, Hermanrud C, Ryner M, Deisenhammer F, Pallardy M, Menge T, Hartung HP, Kieseier BC, Bertotti E, Creeke P, Fogdell-Hahn A, Warnke C.

Front Neurol. 2017 Jul 6;8:305. doi: 10.3389/fneur.2017.00305. eCollection 2017.

4.

Drug Efficacy Monitoring in Pharmacotherapy of Multiple Sclerosis With Biological Agents.

Caldano M, Raoul W, Rispens T, Bertolotto A.

Ther Drug Monit. 2017 Aug;39(4):350-355. doi: 10.1097/FTD.0000000000000393.

5.

MxA mRNA decrease preceding NAb detection in IFNβ-treated MS patients.

Libertinova J, Meluzinova E, Matoska V, Zajac M, Kovarova I, Havrdova E, Horakova D, Tomek A, Marusic P, Bojar M.

Brain Behav. 2017 Feb 9;7(3):e00644. doi: 10.1002/brb3.644. eCollection 2017 Mar.

6.

Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results.

Link J, Ramanujam R, Auer M, Ryner M, Hässler S, Bachelet D, Mbogning C, Warnke C, Buck D, Hyldgaard Jensen PE, Sievers C, Ingenhoven K, Fissolo N, Lindberg R, Grummel V, Donnellan N, Comabella M, Montalban X, Kieseier B, Soelberg Sørensen P, Hartung HP, Derfuss T, Lawton A, Sikkema D, Pallardy M, Hemmer B, Deisenhammer F, Broët P, Dönnes P, Davidson J, Fogdell-Hahn A; ABIRISK Consortium.

PLoS One. 2017 Feb 7;12(2):e0170395. doi: 10.1371/journal.pone.0170395. eCollection 2017.

7.

The cross-reactivity of binding antibodies with different interferon beta formulations used as disease-modifying drugs in multiple sclerosis patients.

Wencel-Warot A, Michalak S, Warot M, Kalinowska-Lyszczarz A, Kazmierski R.

Medicine (Baltimore). 2016 Nov;95(45):e5337.

8.

Blood Biomarkers as Outcome Measures in Inflammatory Neurologic Diseases.

El Ayoubi NK, Khoury SJ.

Neurotherapeutics. 2017 Jan;14(1):135-147. doi: 10.1007/s13311-016-0486-7. Review.

PMID:
27757816
9.

Incidence, characterization, and clinical impact analysis of peginterferon beta1a immunogenicity in patients with multiple sclerosis in the ADVANCE trial.

White JT, Newsome SD, Kieseier BC, Bermel RA, Cui Y, Seddighzadeh A, Hung S, Crossman M, Subramanyam M.

Ther Adv Neurol Disord. 2016 Jul;9(4):239-49. doi: 10.1177/1756285616633967. Epub 2016 Mar 10.

10.

Fatigue and Comorbidities in Multiple Sclerosis.

Fiest KM, Fisk JD, Patten SB, Tremlett H, Wolfson C, Warren S, McKay KA, Berrigan LI, Marrie RA; CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis (ECoMS).

Int J MS Care. 2016 Mar-Apr;18(2):96-104. doi: 10.7224/1537-2073.2015-070.

11.

Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients.

Hegen H, Adrianto I, Lessard CJ, Millonig A, Bertolotto A, Comabella M, Giovannoni G, Guger M, Hoelzl M, Khalil M, Fazekas F, Killestein J, Lindberg RL, Malucchi S, Mehling M, Montalban X, Rudzki D, Schautzer F, Sellebjerg F, Sorensen PS, Deisenhammer F, Steinman L, Axtell RC.

Neurol Neuroimmunol Neuroinflamm. 2016 Jan 27;3(2):e202. doi: 10.1212/NXI.0000000000000202. eCollection 2016 Apr.

12.

Detection of Infertility-related Neutralizing Antibodies with a Cell-free Microfluidic Method.

Eyer K, Root K, Verboket PE, Dittrich PS.

Sci Rep. 2015 Nov 20;5:16551. doi: 10.1038/srep16551.

13.

Treatment strategies for multiple sclerosis: When to start, when to change, when to stop?

Gajofatto A, Benedetti MD.

World J Clin Cases. 2015 Jul 16;3(7):545-55. doi: 10.12998/wjcc.v3.i7.545. Review.

14.

The use of flow cytometry to assess a novel drug efficacy in multiple sclerosis.

Benedek G, Meza-Romero R, Bourdette D, Vandenbark AA.

Metab Brain Dis. 2015 Aug;30(4):877-84. doi: 10.1007/s11011-014-9634-0. Epub 2014 Dec 12. Review.

15.

Neutralizing antibodies and fatigue as predictors of low response to interferon-beta treatment in patients with multiple sclerosis.

Manceau P, Latarche C, Pittion S, Edan G, de Sèze J, Massart C, Debouverie M.

BMC Neurol. 2014 Nov 30;14:215. doi: 10.1186/s12883-014-0215-y.

16.

Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE.

Kieseier BC, Arnold DL, Balcer LJ, Boyko AA, Pelletier J, Liu S, Zhu Y, Seddighzadeh A, Hung S, Deykin A, Sheikh SI, Calabresi PA.

Mult Scler. 2015 Jul;21(8):1025-35. doi: 10.1177/1352458514557986. Epub 2014 Nov 28.

17.

Drug therapy for multiple sclerosis.

Tavazzi E, Rovaris M, La Mantia L.

CMAJ. 2014 Aug 5;186(11):833-40. doi: 10.1503/cmaj.130727. Epub 2014 Apr 22. Review. No abstract available.

18.

MxA mRNA quantification and disability progression in interferon beta-treated multiple sclerosis patients.

Serana F, Imberti L, Amato MP, Comi G, Gasperini C, Ghezzi A, Martinelli V, Provinciali L, Rottoli MR, Sotgiu S, Stecchi S, Vecchio M, Zaffaroni M, Cordioli C, Capra R.

PLoS One. 2014 Apr 14;9(4):e94794. doi: 10.1371/journal.pone.0094794. eCollection 2014.

19.

The effect of scheduled antibody testing on treatment patterns in interferon-treated patients with multiple sclerosis.

Fox E, Green B, Markowitz C, Murray R, Goodman AD, Glenski SJ, Loupe P, Cogburn JN.

BMC Neurol. 2014 Apr 4;14:73. doi: 10.1186/1471-2377-14-73.

20.

Deficient phosphorylation of Stat1 in leukocytes identifies neutralizing antibodies in multiple sclerosis patients treated with interferon-beta.

Gavasso S, Mosleth EF, Marøy T, Jørgensen K, Nakkestad HL, Gjertsen BT, Myhr KM, Vedeler C.

PLoS One. 2014 Feb 19;9(2):e88632. doi: 10.1371/journal.pone.0088632. eCollection 2014.

Supplemental Content

Support Center